{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:00:19Z","timestamp":1767985219705,"version":"3.49.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,8,8]],"date-time":"2016-08-08T00:00:00Z","timestamp":1470614400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"the Science and Technology Commission Foundation of Beijing","award":["Z151100004015143"],"award-info":[{"award-number":["Z151100004015143"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["91542121,81571603"],"award-info":[{"award-number":["91542121,81571603"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s10067-016-3347-1","type":"journal-article","created":{"date-parts":[[2016,8,8]],"date-time":"2016-08-08T06:10:28Z","timestamp":1470636628000},"page":"2715-2721","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["The clinical utility of serum IL-35 in patients with polymyositis and dermatomyositis"],"prefix":"10.1007","volume":"35","author":[{"given":"Liguo","family":"Yin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongpeng","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanbo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinglin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yamei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guochun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,8]]},"reference":[{"key":"3347_CR1","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMra1402225","volume":"372","author":"MC Dalakas","year":"2015","unstructured":"Dalakas MC (2015) Inflammatory muscle diseases. N Engl J Med 372:1734\u20131747","journal-title":"N Engl J Med"},{"key":"3347_CR2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","volume":"362","author":"MC Dalakas","year":"2003","unstructured":"Dalakas MC, Hohlfeld R (2003) Polymyositis and dermatomyositis. Lancet 362:971\u2013982","journal-title":"Lancet"},{"key":"3347_CR3","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJM199111213252107","volume":"325","author":"MC Dalakas","year":"1991","unstructured":"Dalakas MC (1991) Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 325:1487\u20131498","journal-title":"N Engl J Med"},{"key":"3347_CR4","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nrrheum.2011.39","volume":"7","author":"Z Mei","year":"2011","unstructured":"Mei Z, Lundberg IE (2011) Pathogenesis, classification and treatment of inflammatory myopathies. Nat Rev Rheumatol 7:297\u2013306","journal-title":"Nat Rev Rheumatol"},{"key":"3347_CR5","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s11926-000-0082-y","volume":"2","author":"IE Lundberg","year":"2000","unstructured":"Lundberg IE (2000) The role of cytokines, chemokines, and adhesion molecules in the pathogenesis of idiopathic inflammatory myopathies. Curr Rheumatol Rep 2:216\u2013224","journal-title":"Curr Rheumatol Rep"},{"key":"3347_CR6","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nature06306","volume":"450","author":"LW Collison","year":"2007","unstructured":"Collison LW, Workman CJ, Kuo TT, et al. (2007) The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450:566\u2013569","journal-title":"Nature"},{"key":"3347_CR7","doi-asserted-by":"crossref","first-page":"6898","DOI":"10.4049\/jimmunol.181.10.6898","volume":"181","author":"E Bardel","year":"2008","unstructured":"Bardel E, Larousserie F, Charlot-Rabiega P, et al. (2008) Human CD4+CD25+Foxp3+ regulatory T cells do not constitutively express IL-35. J Immunol 181:6898\u20136905","journal-title":"J Immunol"},{"key":"3347_CR8","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1002\/eji.200838373","volume":"38","author":"SE Allan","year":"2008","unstructured":"Allan SE, Song-Zhao GX, Abraham T, et al. (2008) Inducible reprogramming of human T cells into Treg cells by a conditionally active form of FOXP3. Eur J Immunol 38:3282\u20133289","journal-title":"Eur J Immunol"},{"key":"3347_CR9","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/ni.1952","volume":"11","author":"LW Collison","year":"2010","unstructured":"Collison LW, Chaturvedi V, Henderson AL, et al. (2010) IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol 11:1093\u20131101","journal-title":"Nat Immunol"},{"key":"3347_CR10","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cyto.2015.01.019","volume":"73","author":"M Filkova","year":"2015","unstructured":"Filkova M, Vernerova Z, Hulejova H, et al. (2015) Pro-inflammatory effects of interleukin-35 in rheumatoid arthritis. Cytokine 73:36\u201343","journal-title":"Cytokine"},{"key":"3347_CR11","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1128\/CVI.00052-11","volume":"18","author":"J Kuo","year":"2011","unstructured":"Kuo J, Nardelli DT, Warner TF, et al. (2011) Interleukin-35 enhances Lyme arthritis in Borrelia-vaccinated and -infected mice. Clin Vaccine Immunol: CVI 18:1125\u20131132","journal-title":"Clin Vaccine Immunol: CVI"},{"key":"3347_CR12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cyto.2014.05.015","volume":"69","author":"A Thiolat","year":"2014","unstructured":"Thiolat A, Denys A, Petit M, et al. (2014) Interleukin-35 gene therapy exacerbates experimental rheumatoid arthritis in mice. Cytokine 69:87\u201393","journal-title":"Cytokine"},{"key":"3347_CR13","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1002\/eji.200737810","volume":"37","author":"W Niedbala","year":"2007","unstructured":"Niedbala W, Wei XQ, Cai B, et al. (2007) IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol 37:3021\u20133029","journal-title":"Eur J Immunol"},{"key":"3347_CR14","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nm.3554","volume":"20","author":"RX Wang","year":"2014","unstructured":"Wang RX, Yu CR, Dambuza IM, et al. (2014) Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat Med 20:633\u2013641","journal-title":"Nat Med"},{"key":"3347_CR15","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"APJ Bohan","year":"1975","unstructured":"Bohan APJ (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292:403\u2013407","journal-title":"N Engl J Med"},{"key":"3347_CR16","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"APJ Bohan","year":"1975","unstructured":"Bohan APJ (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344\u2013347","journal-title":"N Engl J Med"},{"key":"3347_CR17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/rheumatology\/keg427","volume":"43","author":"DA Isenberg","year":"2004","unstructured":"Isenberg DA, Allen E, Farewell V, et al. (2004) International consensus outcome measures for patients with idiopathic inflammatory myopathies development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 43:49\u201354","journal-title":"Rheumatology (Oxford)"},{"key":"3347_CR18","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/nature07036","volume":"453","author":"E Bettelli","year":"2008","unstructured":"Bettelli E, Korn T, Oukka M, et al. (2008) Induction and effector functions of T(H)17 cells. Nature 453:1051\u20131057","journal-title":"Nature"},{"key":"3347_CR19","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1084\/jem.181.3.839","volume":"181","author":"L Llorente","year":"1995","unstructured":"Llorente L, Zou W, Levy Y, et al. (1995) Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 181:839\u2013844","journal-title":"J Exp Med"},{"key":"3347_CR20","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.4049\/jimmunol.145.12.4167","volume":"145","author":"IA Macneil","year":"1990","unstructured":"Macneil IA, Suda T, Moore KW, et al. (1990) IL-10, a novel growth cofactor for mature and immature T cells. J Immunol 145:4167\u20134173","journal-title":"J Immunol"},{"key":"3347_CR21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1189\/jlb.0612293","volume":"93","author":"I Shachar","year":"2013","unstructured":"Shachar I, Karin N (2013) The dual roles of inflammatory cytokines and chemokines in the regulation of autoimmune diseases and their clinical implications. J Leukoc Biol 93:51\u201361","journal-title":"J Leukoc Biol"},{"key":"3347_CR22","doi-asserted-by":"crossref","unstructured":"Cai Z, Wong CK, Kam NW, et al. (2015) Aberrant expression of regulatory cytokine IL-35 in patients with systemic lupus erythematosus. Lupus 24","DOI":"10.1177\/0961203315585815"},{"key":"3347_CR23","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1177\/0961203313498799","volume":"22","author":"F Qiu","year":"2013","unstructured":"Qiu F, Song L, Yang N, et al. (2013) Glucocorticoid downregulates expression of IL-12 family cytokines in systemic lupus erythematosus patients. Lupus 22:1011\u20131016","journal-title":"Lupus"},{"key":"3347_CR24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/08916930802282651","volume":"42","author":"L Banica","year":"2009","unstructured":"Banica L, Besliu A, Pistol G, et al. (2009) Quantification and molecular characterization of regulatory T cells in connective tissue diseases. Autoimmunity 42:41\u201349","journal-title":"Autoimmunity"},{"key":"3347_CR25","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jaut.2010.07.006","volume":"35","author":"E Antiga","year":"2010","unstructured":"Antiga E, Kretz CC, Klembt R, et al. (2010) Characterization of regulatory T cells in patients with dermatomyositis. J Autoimmun 35:342\u2013350","journal-title":"J Autoimmun"},{"key":"3347_CR26","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1007\/s10067-012-2075-4","volume":"31","author":"DX Wang","year":"2012","unstructured":"Wang DX, Lu X, Zu N, et al. (2012) Clinical significance of peripheral blood lymphocyte subsets in patients with polymyositis and dermatomyositis. Clin Rheumatol 31:1691\u20131697","journal-title":"Clin Rheumatol"},{"key":"3347_CR27","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1046\/j.1365-2249.1998.00664.x","volume":"113","author":"Nagaraju","year":"1998","unstructured":"Nagaraju, Raben, Merritt, et al. (1998) A variety of cytokines and immunologically relevant surface molecules are expresssed by normal skeletal muscle cells under proinflammatory stimuli. Clin Exp Immunol 113:407\u2013414","journal-title":"Clin Exp Immunol"},{"key":"3347_CR28","doi-asserted-by":"crossref","first-page":"440","DOI":"10.2353\/ajpath.2009.080752","volume":"175","author":"S Kempe","year":"2009","unstructured":"Kempe S, Heinz P, Kokai E, et al. (2009) Epstein-barr virus-induced gene-3 is expressed in human atheroma plaques. Am J Pathol 175:440\u2013447","journal-title":"Am J Pathol"},{"key":"3347_CR29","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0165-5728(02)00362-4","volume":"133","author":"JMV Seventer","year":"2002","unstructured":"Seventer JMV, Nagai T, Seventer GAV (2002) Interferon-beta differentially regulates expression of the IL-12 family members p35, p40, p19 and EBI3 in activated human dendritic cells. J Neuroimmunol 133:60\u201371","journal-title":"J Neuroimmunol"},{"key":"3347_CR30","doi-asserted-by":"crossref","first-page":"G1315","DOI":"10.1152\/ajpgi.00142.2007","volume":"293","author":"J Heidemann","year":"2008","unstructured":"Heidemann J, R\u00fcther C, Kebschull M, et al. (2008) Expression of IL-12-related molecules in human intestinal microvascular endothelial cells is regulated by TLR3. Am J Physiol Gastrointest Liver Physiol 293:G1315\u2013G1324","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"3347_CR31","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1365-2567.2004.01895.x","volume":"112","author":"C Maaser","year":"2004","unstructured":"Maaser C, Egan LJ, Birkenbach MP, et al. (2004) Expression of Epstein-Barr virus-induced gene 3 and other interleukin-12-related molecules by human intestinal epithelium. Immunology 112:437\u2013445","journal-title":"Immunology"},{"key":"3347_CR32","first-page":"65","volume":"7","author":"L Xinyuan","year":"2012","unstructured":"Xinyuan L, Jietang M, Anthony V, et al. (2012) IL-35 is a novel responsive anti-inflammatory cytokine\u2014a new system of categorizing anti-inflammatory cytokines. PLoS One 7:65\u201365","journal-title":"PLoS One"},{"key":"3347_CR33","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/art.1780330908","volume":"33","author":"IN Targoff","year":"1990","unstructured":"Targoff IN, Johnson AE, Miller FW (1990) Antibody to signal recognition particle in polymyositis. Arthritis Rheum 33:1361\u20131370","journal-title":"Arthritis Rheum"},{"key":"3347_CR34","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/art.11484","volume":"50","author":"AH Kao","year":"2004","unstructured":"Kao AH, David L, Mary L, et al. (2004) Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 50:209\u2013215","journal-title":"Arthritis Rheum"},{"key":"3347_CR35","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.pharep.2014.10.015","volume":"67","author":"W Skowron","year":"2015","unstructured":"Skowron W, Zemanek K, Wojdan K, et al. (2015) The effect of interleukin-35 on the integrity, ICAM-1 expression and apoptosis of human aortic smooth muscle cells. Pharmacol Rep: PR 67:376\u2013381","journal-title":"Pharmacol Rep: PR"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-016-3347-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-016-3347-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-016-3347-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T15:20:28Z","timestamp":1692458428000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-016-3347-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,8]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["3347"],"URL":"https:\/\/doi.org\/10.1007\/s10067-016-3347-1","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,8]]}}}